Press release
Pegfilgrastim Biosimilars Market 2021 : Trends, Business Growth And Major Driving Factors
Pegfilgrastim Biosimilars Market
https://www.thebusinessresearchcompany.com/global-market-reports
‘Pegfilgrastim Biosimilars Global Market Report 2021 – COVID-19 Growth And Change’ by The Business Research Company is the most comprehensive report available on this market, with analysis of the market’s historic and forecast growth, drivers and restraints causing this, and highlights of the opportunities that companies in the industry can take on. The market research report helps gain a truly global perspective of the pegfilgrastim biosimilars industry as it covers 60 geographies. Regional and country breakdowns give an analysis of the market in each geography, with information on the size of the market by region and by country.
The countries covered in the global pegfilgrastim biosimilars market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.
The regions covered in the global pegfilgrastim biosimilars market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Know What You Need? Directly Purchase The Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015
The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.
The global pegfilgrastim biosimilars market is expected to grow from $0.8 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.42 billion in 2025 at a CAGR of 13%.
Request For A Sample Of The Pegfilgrastim Biosimilars Market Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp
The global pegfilgrastim biosimilars market is segmented -
1) By Application: Chemotherapy Treatment, Transplantation, Others
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.
Need More? Read Further On The Pegfilgrastim Biosimilars Market Here:
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-global-market
The Table of Contents includes:
1. Executive Summary
2. Pegfilgrastim Biosimilars Market Characteristics
3. Pegfilgrastim Biosimilars Market Trends And Strategies
4. Impact Of COVID-19 On Pegfilgrastim Biosimilars
5. Pegfilgrastim Biosimilars Market Size And Growth
.....
28. Pegfilgrastim Biosimilars Pipeline Analysis
29. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market
30. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis
31. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Interested to know more about The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Get a glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegfilgrastim Biosimilars Market 2021 : Trends, Business Growth And Major Driving Factors here
News-ID: 2466001 • Views: …
More Releases from The Business research company
Artificial Intelligence (AI) In Clinical Trials Market 2024 - Size, Share, Trend …
The artificial intelligence (ai) in clinical trials market size has grown exponentially in recent years. It will grow from $1.52 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 28.1%. The growth in the historic period can be attributed to increasing data complexity, rising costs and time constraints, regulatory demands, early ai applications, patient-centric approaches.
The artificial intelligence (ai) in clinical trials…
Serum Free Media Market 2024 - Size, Trends, Opportunities, and Forecasting unti …
The serum free media market size has grown rapidly in recent years. It will grow from $1.45 billion in 2023 to $1.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to cell culture advancements, regulatory restrictions, demand for biopharmaceuticals, reduction in contamination risk.
The serum free media market size is expected to see rapid growth in…
Biologics Outsourcing Market 2024 - Share Analysis, Top Companies' Influence, Re …
The biologics outsourcing market size has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $20.33 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing r&d costs, regulatory pressure, demand for specialized expertise, globalization.
The biologics outsourcing market size is expected to see rapid growth in the next few years.…
Gastrointestinal Endoscopy Market 2024 - Size, Share Analysis, Insights into Fut …
The gastrointestinal endoscopy market size has grown strongly in recent years. It will grow from $14.65 billion in 2023 to $15.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of gastrointestinal disorders, rising awareness about early disease detection, growing aging population, reimbursement policies, expanding applications in therapeutic procedures.
The gastrointestinal endoscopy market size…
More Releases for Pegfilgrastim
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia.
Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Neutropenia patients are highly…
Global Pegfilgrastim Market to 2026 - Industry Perspective, Comprehensive Analys …
The Pegfilgrastim Market report is intended to function as a supportive means to assess the Pegfilgrastim market ( https://bit.ly/37xB0L8 ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the clients in decision-making by presenting knowledgeable…
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts.
Pegfilgrastim is a PEGylated…
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…
Pegfilgrastim Biosimilar Market Estimated to Record Highest CAGR by 2018 to 2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…
Pegfilgrastim Industry Business Outlook and Procurement Survey To 2017
Market Reports Center has released its latest research-based report entitled ‘Pegfilgrastim market.' This comprehensive report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Pegfilgrastim market worldwide along with the key trends and latest technologies, playing a prominent role in the Pegfilgrastim market growth over the predicted period. It also takes into account the market trends, aspects like…
